IFNA1 and neoplasm: The humanized mice were randomly assigned to treatment and control groups (Figure 2a) and vaccinated three times at seven-day intervals via intraperitoneal administration of autologous IFN-DC loaded with HOCl-oxidized tumor cell lysate.